GlassScriptPhysician profile
Frank Nelson Burks
NPI 1659585198
$3,383.10
in general payments reported to CMS, 2019-2025
39 companies · $694 in 2025
The $694 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $310 · 2020: $126 · 2021: $233 · 2022: $671 · 2023: $672 · 2024: $676 · 2025: $694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,874 · Education: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,874.47 |
| Education | $167.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $531.89 | 2019-2024 | Titan |
| Boston Scientific Corporation | $483.97 | 2019-2023 | |
| Astellas Pharma US INC | $417.27 | 2021-2025 | Xtandi, Myrbetriq |
| Sumitomo Pharma America, INC. | $358.51 | 2023-2025 | Orgovyx, Gemtesa |
| Calyxo, INC. | $144.69 | 2025 | Cvac Aspiration System |
| Janssen Biotech, INC. | $132.45 | 2019-2025 | Erleada |
| Olympus America INC. | $127.41 | 2019-2025 | Itind System |
| Ferring Pharmaceuticals INC. | $127.36 | 2024-2025 | Adstiladrin |
| Myovant Sciences INC. | $122.18 | 2022 | |
| Antares Pharma, INC. | $81.12 | 2022-2025 | Xyosted |
| Blue Earth Diagnostics | $76.19 | 2020-2021 | |
| Pfizer INC. | $67.08 | 2024-2025 | |
| Abbvie INC. | $65.88 | 2021-2025 | |
| Laborie Medical Technologies Corp. | $62.41 | 2022-2025 | |
| Urogen Pharma, INC. | $53.64 | 2021-2024 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $47.94 | 2021-2024 | Provenge |
| Photocure INC | $45.81 | 2023-2025 | Cysview |
| Tempus Ai, INC | $32.72 | 2024 | |
| Tolmar Pharmaceuticals, INC. | $30.17 | 2022 | |
| Avyxa Pharma, LLC | $29.71 | 2025 | |
| Progenics Pharmaceuticals, INC. | $28.16 | 2024 | |
| Analogic Corporation | $26.55 | 2019 | |
| Merck Sharp & Dohme LLC | $21.38 | 2023 | Keytruda, Lynparza |
| 180 Medical, INC. | $21.17 | 2021 | |
| Endo USA, INC. | $20.75 | 2025 | Xiaflex, Aveed |
| Immunitybio, INC. | $20.45 | 2025 | |
| Novartis Pharmaceuticals Corporation | $20.43 | 2024 | |
| Integra Lifesciences Corporation | $19.88 | 2024 | Integra, Integra Dermal Regeneration Template, Omnigraft |
| Curium US LLC | $18.85 | 2023 | |
| Rochester Medical Corporation | $18.83 | 2021 | |
| Tolmar, INC. | $17.03 | 2023 | |
| Cycle Pharmaceuticals INC | $16.40 | 2025 | Venxxiva |
| Accord Healthcare, INC. | $16.28 | 2023 | |
| Axonics, INC. | $16.00 | 2020 | |
| Srs Medical Systems, INC. | $15.72 | 2023 | Urocuff |
| Clovis Oncology, INC. | $14.73 | 2020 | |
| Allergan, INC. | $12.86 | 2021 | |
| Acerus Pharmaceuticals Corporation | $12.44 | 2020 | |
| Ambu INC. | $6.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Burks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.